查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1735703

全球脊髓灰质炎疫苗市场规模（依脊髓灰质炎疫苗类型、应用、区域范围、预测）

Global Polio Vaccine Market Size By Polio Vaccine Type, By Application, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

脊髓灰质炎疫苗市场规模及预测

2024 年脊髓灰质炎疫苗市场规模价值 6.995 亿美元，预计到 2032 年将达到 10.6781 亿美元，2026 年至 2032 年的复合年增长率为 4.6%。

全球脊髓灰质炎疫苗市场驱动因素

脊髓灰质炎疫苗市场的市场驱动因素可能受到多种因素的影响，其中包括：

  • 政府努力和疫苗接种计划 许多国家与联合国儿童基金会和世界卫生组织 (WHO) 等国际组织合作开展了大规模疫苗宣传活动，以消灭脊髓灰质炎，大大增加了对脊髓灰质炎疫苗的需求。
  • 部分地区脊髓灰质炎发生率上升：儘管国际社会做出了努力，但脊髓灰质炎仍在部分地区持续蔓延，尤其是在亚洲和非洲。各国正加强疫苗接种工作，以控制脊髓灰质炎并阻止其蔓延。
  • 疫苗技术发展：疫苗技术的新突破，例如更安全、更有效的疫苗的研发，正在推动市场扩张。新的给药方式和疫苗配方的改进，是有助于提高疫苗接种率和有效性的一些进步。
  • 知识和医疗支出的增加：这个市场是由许多国家对疫苗接种价值的认识不断加深以及医疗支出不断增加所驱动的。随着政府和非政府组织加强对医疗机构和疫苗接种计画的投资，疫苗需求正在上升。
  • 全球根除脊髓灰质炎行动：像全球根除脊髓灰质炎行动 (GPEI) 这样的组织透过为世界各地的免疫计画提供资金和援助，在推动市场发展方面发挥着至关重要的作用。他们的工作对于维持高免疫接种率和追踪脊髓灰质炎疫情至关重要。
  • 开发中国家出生率上升：开发中国家出生率上升导致符合脊髓灰质炎疫苗接种条件的目标人口增加。这一人口方面影响着脊髓灰质炎疫苗接种的持续需求。
  • 伙伴关係与合作：政府、非政府组织 (NGO) 和私营部门之间的合作可以提高脊髓灰质炎疫苗宣传活动的有效性和覆盖面，并有助于扩大市场。
  • 根除脊髓灰质炎的经济效益：根除脊髓灰质炎具有降低医疗成本、提高生产力等经济效益，鼓励政府和组织投资疫苗接种计划，进而增加市场需求。
  • 监管支持与核准：有利的新型疫苗法律规范以及美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 的快速核准，促进了该行业的扩张。监管支持确保了疫苗的及时分发和供应。

限制全球脊髓灰质炎疫苗市场的因素

脊髓灰质炎疫苗市场面临许多阻碍因素和挑战，包括：

  • 生产挑战：生产脊髓灰质炎疫苗需要严格的品管和生物安全程序。任何干扰生产过程的因素，例如污染或设备故障，都可能导致供不应求。
  • 低温运输物流：脊髓灰质炎疫苗，尤其是口服脊髓灰质炎疫苗 (OPV)，必须在特定温度下运输和储存才能保持有效。低温运输设施不足会使疫苗分发变得复杂，尤其是在低收入者身上。
  • 资金限制：脊髓灰质炎疫苗宣传活动通常由政府和国际组织资助。资金不足可能会限制疫苗接种的覆盖率和覆盖范围。
  • 疫苗接种计画成本：疫苗接种计画成本：实施大规模疫苗接种计画会产生各种成本，包括人员配备、物流、公众意识提升宣传活动等。疫苗接种的频率和覆盖率可能会受到财务限制的影响。
  • 政治不稳定：在政治不稳定或暴力事件频繁的地区，由于人口流动和安全问题，可能难以进行定期的大规模疫苗宣传活动。
  • 疫苗犹豫：由于错误讯息和对疫苗接种的不信任，社区居民可能对疫苗接种犹豫不决。对疫苗有效性和安全性的误解和文化观念可能会降低疫苗接种率。
  • 监管部门核准：获得全新疫苗或已核准疫苗的变更的监管部门批准是一个困难且漫长的过程。
  • 政策差异：各国的卫生政策和法律规范各不相同，这可能会使脊髓灰质炎免疫的国际分发和吸收变得复杂。
  • 新出现的健康危机：其他疾病（例如新冠肺炎）的爆发可能会导致脊髓灰质炎疫苗接种宣传活动的关注和资金减少。卫生系统可能会优先考虑当前风险，而不是持续的根除脊髓灰质炎的努力。
  • 疫苗研发：研发新的改良的脊髓灰质炎疫苗，包括更容易接种和提供更持久免疫力的疫苗，成本高且技术难度高。
  • 技术创新停滞：高成本和风险问题可能会阻碍疫苗技术的创新，从而阻碍市场成长。
  • 近乎根除的挑战：一旦脊髓灰质炎几乎被彻底根除，人们可能不再愿意接种疫苗，这可能导致疫苗接种率下降。

目录

第一章 全球脊髓灰质炎疫苗市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章 全球脊髓灰质炎疫苗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球脊髓灰质炎疫苗市场（以脊髓灰质炎疫苗类型）

  • 概述
  • 口服脊髓灰质炎疫苗（OPV）
  • 灭活脊髓灰质炎疫苗（IPV）

第六章 全球脊髓灰质炎疫苗市场（依应用）

  • 概述
  • 公共
  • 私人的

第七章全球脊髓灰质炎疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

8. 全球脊髓灰质炎疫苗市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Astellas Pharma
  • Serum Institute of India Pvt. Ltd.
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Panacea Biotec Ltd

第十章 附录

  • 相关调查
简介目录
Product Code: 35696

Polio Vaccine Market Size And Forecast

Polio Vaccine Market size is valued at USD 699.5 Million in the year 2024 and is projected to reach USD 1067.81 Million in 2032, growing at a CAGR of 4.6% from 2026 to 2032.

Global Polio Vaccine Market Drivers

The market drivers for the Polio Vaccine Market can be influenced by various factors. These may include:

  • Government Initiatives and Vaccination Programmes: In an effort to end polio, numerous nations have started massive vaccination campaigns in cooperation with international agencies like UNICEF and the World Health Organisation (WHO). The need for polio vaccines is greatly fueled by these initiatives.
  • Growing Polio Incidence in Some Areas: In spite of international efforts, polio outbreaks continue to happen, especially in some areas of Asia and Africa. Vaccination efforts are stepped up in response to these outbreaks in an attempt to contain and stop the disease's spread.
  • Technological Developments in Vaccines: New developments in vaccine technology, such as the creation of safer and more effective vaccinations, support market expansion. Novel delivery methods and improved vaccine formulations are examples of advances that increase immunisation uptake and efficacy.
  • Growing Knowledge and Healthcare Spending: The market is supported by growing knowledge of the value of vaccinations as well as growing healthcare spending in many nations. The demand for vaccines is rising as governments and non-governmental organisations invest more in healthcare facilities and immunisation programmes.
  • Global Polio Eradication Initiatives: By providing money and assistance for vaccination programmes worldwide, organisations such as the Global Polio Eradication Initiative (GPEI) are crucial in propelling the market. Their work is essential to keeping a high immunisation rate and tracking polio outbreaks.
  • Rising Birth Rates in Developing Nations: A greater target population for polio vaccination is produced by rising birth rates in developing nations. The ongoing need for polio immunisations is influenced by this demographic aspect.
  • Partnerships and Collaborations: Governments, non-governmental organisations (NGOs), and businesses in the private sector work together to improve the efficacy and reach of polio vaccine campaigns, which propels market expansion.
  • Economic Gains from Polio Eradication: Governments and organisations are encouraged to invest in vaccination programmes by the financial gains from polio eradication, which include lower healthcare expenses and increased productivity. This increases demand in the market.
  • Regulatory Support and Approvals: The expansion of the industry is facilitated by favourable regulatory frameworks and expedited FDA and EMA approvals for novel vaccines. The timely distribution and availability of vaccines is guaranteed by regulatory support.

Global Polio Vaccine Market Restraints

Several factors can act as restraints or challenges for the Polio Vaccine Market . These may include:

  • Manufacturing Difficulties: Strict quality control and biosafety procedures are needed during the production of polio vaccines. Shortages of supplies can result from any interference with the manufacturing process, including contamination and equipment malfunctions.
  • Cold Chain Logistics: To preserve their effectiveness, polio vaccines, especially the oral polio vaccine (OPV), must be transported and stored at a certain temperature. Inadequate cold chain facilities can make it more difficult to distribute vaccines, particularly in low-income areas.
  • Financial Restraints: Governments and international organisations are frequently the source of funding for polio immunisation campaigns. The extent of immunisation efforts and the availability of vaccinations may be restricted by a lack of financing.
  • Cost of Vaccination Programmes: The expenses associated with putting in place extensive vaccination programmes, such as those related to staffing, logistics, and public awareness campaigns, can add up. The frequency and reach of vaccination drives might be impacted by financial limitations.
  • Political Instability: Because of population dislocation and security concerns, areas undergoing political unrest or violence may find it challenging to implement regular and extensive vaccination campaigns.
  • Vaccine hesitation: In communities, vaccine hesitation can be caused by misinformation and mistrust of vaccinations. Misconceptions and cultural beliefs regarding the effectiveness and safety of vaccinations can lower vaccination rates.
  • Regulatory Approvals: Getting regulatory permission for brand-new vaccines or modifications to already-approved ones may be a difficult and drawn-out procedure, which may cause a delay in the product's release onto the market.
  • Policy Variations: Health policies and regulatory frameworks differ among nations, which might make it more difficult for polio vaccinations to be distributed and accepted internationally.
  • Emerging Health Crises: Polio vaccination campaigns may receive less attention and funding as a result of outbreaks of other diseases like COVID-19. Health systems can give priority to current risks over ongoing efforts to eradicate polio.
  • Vaccine Development: It can be expensive and technically difficult to create new and improved polio vaccines, such as those that offer easier administration or longer-lasting immunity.
  • Innovation Stagnation: The market's ability to grow may be hampered by a lack of innovation in vaccination technology as a result of high costs and risk issues.
  • Challenges associated with near-eradication: As polio is almost completely eradicated, people may become less inclined to get vaccinated, which could result in a decline in vaccination rates. There is a chance that this will resurface.

Global Polio Vaccine Market Segmentation Analysis

The Global Polio Vaccine Market is Segmented on the basis of Polio Vaccine Type, Application, and Geography.

Polio Vaccine Market, By Polio Vaccine Type

  • Oral Polio Vaccine (OPV)
  • Inactivated Poliomyelitis Vaccine (IPV)
  • Based on Polio Vaccine Type, the market is bifurcated into, Oral Polio Vaccine (OPV), Inactivated Poliomyelitis Vaccine (IPV). OralPolio Vaccine is leading in the segment used in the fight to eradicate polio and it can replicate effectively in the intestine which enables an individual to mount an immune response against the virus

Polio Vaccine Market, By Application

  • Public
  • Private
  • Based on Application, the market is bifurcated into the public and private segments. The public segment is estimated to hold the largest share. Government policies and their fight to eradicate polio has been the major cause for the growth of the segment

Polio Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, the Global Polio Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Asia Pacific region is leading in the segment and holds the largest industry in the globe, as the number of polio vaccination is highest in the region. North America and Europe also hold a decent amount of share in the market

Key Players

  • The major players in the Polio Vaccine Market are:
  • Pfizer
  • Sanofi, Astellas Pharma
  • Serum Institute of India Pvt. Ltd.
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Panacea Biotec Ltd.
  • GlaxoSmithKline (UK)
  • Bharat Biotech (India)
  • China National Biotec Group (China)
  • Walvax Biotechnology Co., Ltd. (China)
  • IMVAM (Canada)

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL POLIO VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL POLIO VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL POLIO VACCINE MARKET, BY POLIO VACCINE TYPE

  • 5.1 Overview
  • 5.2 Oral Polio Vaccine (OPV)
  • 5.3 Inactivated Poliomyelitis Vaccine (IPV)

6 GLOBAL POLIO VACCINE MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Public
  • 6.3 Private

7 GLOBAL POLIO VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East And Africa

8 GLOBAL POLIO VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Pfizer
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 GlaxoSmithKline
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Sanofi
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Astellas Pharma
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Serum Institute of India Pvt. Ltd.
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Haffkine Bio-Pharmaceutical Corporation Ltd.
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Panacea Biotec Ltd
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments

10 Appendix

  • 10.1 Related Research